GlassScriptPhysician profile
Robert B Freele
NPI 1851317101
$9,130.09
in general payments reported to CMS, 2019-2025
35 companies · $1,738 in 2025
The $1,738 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,537 · 2020: $692 · 2021: $818 · 2022: $1,413 · 2023: $659 · 2024: $1,274 · 2025: $1,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,464 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,463.87 |
| Education | $206.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,367.22 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,066.10 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $876.69 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Allergan, INC. | $669.94 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $666.03 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $586.16 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $491.80 | 2019-2022 | |
| Alkermes, INC. | $372.20 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Neuronetics, INC. | $357.01 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $292.10 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $243.17 | 2019-2025 | Invega Sustenna, Spravato |
| Lundbeck LLC | $241.64 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $239.85 | 2021-2025 | Caplyta |
| Corium, LLC | $189.33 | 2022-2025 | Azstarys |
| Neos Therapeutics, LP | $182.86 | 2019-2025 | Adzenys Xr-Odt |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $124.76 | 2019 | |
| Idorsia Pharmaceuticals US INC | $123.13 | 2023 | Quviviq |
| Bausch Health US, LLC | $122.69 | 2019-2024 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $111.09 | 2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $109.80 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $100.29 | 2019-2022 | |
| Shire North American Group INC | $82.74 | 2019 | |
| Tris Pharma INC | $72.50 | 2019-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $71.06 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $70.89 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $68.48 | 2019-2020 | |
| Indivior INC. | $57.87 | 2019-2024 | Perseris |
| Noven Therapeutics, LLC | $38.55 | 2023-2025 | Secuado, Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $35.95 | 2024 | Trintellix |
| Orexo US, INC. | $20.22 | 2021 | |
| Livanova USA, INC. | $19.38 | 2020 | |
| Vertical Pharmaceuticals, LLC | $15.90 | 2019 | |
| Adlon Therapeutics L.P. | $14.87 | 2019 | |
| Eisai INC. | $14.49 | 2021 | |
| Alfasigma USA, INC. | $13.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Freele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.